SCHEMBL6130170

SCHEMBL6130170

C=CCNc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
TYMS P04818 7/20 0.54
POLA1 P09884 1/20 0.53
POLD1 P28340 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6129081 0.94 POLB (0.52) POLBTYMSPOLA1POLD1
SCHEMBL6129083 0.94 POLB (0.52) POLBTYMSPOLA1POLD1
SCHEMBL8059303 0.91 TYMS (0.64) TYMS
SCHEMBL18152601 0.86 POLB (0.56) POLBTYMSPOLA1POLD1
SCHEMBL22322707 0.85 TYMS (0.65) POLBTYMSPOLA1POLD1
SCHEMBL7752314 0.85 TYMS (0.50) POLBTYMS
Lithium Ion SCHEMBL8844072 0.84 TYMS (0.49) POLBTYMS
Biotin SCHEMBL9328971 0.83 F2 (0.46) POLBTYMSPOLA1POLD1
SCHEMBL6462543 0.83 POLB (0.62) POLBTYMSPOLA1POLD1
SCHEMBL149769 0.83 POLB (0.62) POLBTYMSPOLA1POLD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6054442-A THE INCORPORATION OF NUCLEOTIDE ANALOGS, SUCH AS 7-DEAZA-2'-DEOXYQUANOSINE-5'-TRIPHOSPHATE AFFECTED THE PROCESSIVITY OF TELOMERASE, CONVERTING PROCESSIVE TELOMERASE TO NON-PROCESSIVE TELOMERASE. BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM 2000-04-25 US claimed
EP-1326523-A4 IMAGING OF ENZYMATIC ACTIVITY GEN HOSPITAL CORP (US) 2005-01-05 EP disclosed
US-20040241096-A1 Detect enzyme activity in sample; incubation target tissue; detect amplification in sample THE GENERAL HOSPITAL CORPORATION, A MASSACHUSETTS CORPORATION 2004-12-02 US disclosed
US-6737247-B2 DETECTING ENZYMATIC ACTIVITY IN SAMPLE; OBTAIN SUBSTRATE, INCUBATE WITH TARGET TISSUE, DETECT AMPLIFIED RELAXIVITY OF SAMPLE, EVALUATE ENZYMATIC ACTIVITY SAMPLE THE GENERAL HOSPITAL CORPORATION 2004-05-18 US disclosed
EP-1326523-A2 IMAGING OF ENZYMATIC ACTIVITY THE GENERAL HOSPITAL CORPORATION (US) 2003-07-16 EP disclosed
US-6593306-B1 Prematurely shortening a telomere in a cell comprising administering to said cell in an animal in an amount of 7-deaza nucleoside in an amount sufficient to inhibit telomere extension, reduced proliferative capacity leads to cell death BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS 2003-07-15 US disclosed
WO-2002032291-A9 IMAGING OF ENZYMATIC ACTIVITY GEN HOSPITAL CORP (US) 2003-04-17 WO disclosed
US-20020127629-A1 Imaging of enzymatic activity NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-09-12 US disclosed
WO-2002032291-A2 IMAGING OF ENZYMATIC ACTIVITY THE GENERAL HOSPITAL CORPORATION (US) 2002-04-25 WO disclosed
EP-0798387-B1 Method of detecting nucleic acid TOYODA CHUO KENKYUSHO KK (JP) 2001-01-24 EP disclosed
US-6004939-A INHIBITING CELL GROWTH WITH 7-DEAZA-2*-DEOXYNUCLEOSIDE; ANTICARCINOGENIC AGENTS CTRC RESEARCH FOUNDATION BOARD OF REGENTS (US) 1999-12-21 US disclosed
US-5728531-A HYBRIDIZING DNA PROBE LABELED WITH A GIBBERELLIN TO A NUCLEIC ACID, BINDING LABELED ANTIBODY TO HYBRID AND DETECTING LABELED ANTIBODY AND THEREBY THE NUCLEIC ACID KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) 1998-03-17 US disclosed
EP-0798387-A1 Method of detecting nucleic acid KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) 1997-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020127629-A1 Imaging of enzymatic activity MMP1, ENGASE, MMP2 POLB 1682/4885TYMS 2319/4885POLA1 774/4885
US-20040241096-A1 Detect enzyme activity in sample; incubation target tissue; detect amplification in sample MMP1, ENGASE, MMP2 POLB 288/4885TYMS 2409/4885POLA1 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.